Skip to main content

Advertisement

SpringerLink
Log in

Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Second-generation azoles may be more effective than first-generation azoles in the prevention of fungal infections in hematology patients. We performed a systematic review with meta-analysis of randomized controlled trials comparing second- with first-generation azoles in hematology patients with respect to proven or probable invasive fungal infections, invasive aspergillosis, receipt of empirical antifungal therapy, overall mortality, and withdrawal from the studies due to the development of adverse effects. We searched the Medline, Embase, and Cochrane Registry of Controlled Trials electronic databases as well as conference proceedings from 2002 to 2012 for randomized controlled trials comparing second-generation azoles (voriconazole, posaconazole) versus first-generation azoles (fluconazole, itraconazole). Treatment effect measures for all outcomes were expressed as odds ratio with 95 % confidence interval. Meta-analysis was performed using Review Manager, version 5.1. Data from four randomized clinical trials representing a large population of patients demonstrated that antifungal prophylaxis with second-generation azoles reduces proven or probable invasive fungal infections, invasive aspergillosis, and receipt of empirical antifungal therapy in high-risk hematology patients, while there were no differences between second- and first-generation azoles with regard to overall mortality and patients or withdrawal from the studies due to the development of adverse effects. In conclusion, antifungal prophylaxis with second-generation azoles can significantly reduce the incidence of invasive fungal infections and invasive aspergillosis but with no risk of an increase in adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Wirk B, Wingard JR (2009) Current approaches in antifungal prophylaxis in high-risk hematologic malignancy and hematopoietic stem cell transplant patients. Mycopathologia 168:299–311

    Article  PubMed  Google Scholar 

  2. Kale P, Johnson LB (2005) Second-generation azole antifungal agents. Drugs Today (Barc) 41:91–105

    Article  CAS  Google Scholar 

  3. Girmenia C (2009) New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 18:1279–1295

    Article  PubMed  CAS  Google Scholar 

  4. Cornely OA, Maertens J, Winston DJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359

    Article  PubMed  CAS  Google Scholar 

  5. Ullmann AJ, Lipton JH, Vesole DH et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335–347

    Article  PubMed  CAS  Google Scholar 

  6. Wingard JR, Carter SL, Walsh TJ et al (2010) Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116:5111–5118

    Article  PubMed  CAS  Google Scholar 

  7. Marks DI, Pagliuca A, Kibbler CC et al (2011) Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 155:318–327

    Article  PubMed  CAS  Google Scholar 

  8. Ananda-Rajah MR, Grigg A, Downey MT et al (2012) Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica 97:459–463

    Article  PubMed  CAS  Google Scholar 

  9. Ascioglu S, Rex JH, de Pauw B et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14

    Article  PubMed  CAS  Google Scholar 

  10. Pagano L, Caira M, Nosari A et al (2007) Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study—Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 45:1161–1170

    Article  PubMed  CAS  Google Scholar 

  11. Neofytos D, Horn D, Anaissie E et al (2009) Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 48:265–273

    Article  PubMed  CAS  Google Scholar 

  12. Kontoyiannis DP, Marr KA, Park BJ et al (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50:1091–1100

    Article  PubMed  Google Scholar 

  13. Vardakas KZ, Michalopoulos A, Falagas ME (2005) Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 131:22–28

    Article  PubMed  CAS  Google Scholar 

  14. Maertens J, Marchetti O, Herbrecht R et al (2011) European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant 46:709–718

    Article  PubMed  CAS  Google Scholar 

  15. Greer ND (2003) Voriconazole: the newest triazole antifungal agent. Proc (Bayl Univ Med Cent) 16:241–248

    Google Scholar 

  16. Cornely OA, Bohme A, Buchheidt D et al (2009) Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94:113–122

    Article  PubMed  Google Scholar 

  17. Hicheri Y, Cook G, Cordonnier C (2012) Antifungal prophylaxis in haematology patients: the role of voriconazole. Clin Microbiol Infect 18(Suppl 2):1–15

    Article  PubMed  CAS  Google Scholar 

  18. Nagappan V, Deresinski S (2007) Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 45:1610–1617

    Article  PubMed  CAS  Google Scholar 

  19. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II (2005) Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 5:775–785

    Article  PubMed  CAS  Google Scholar 

  20. Hamprecht A, Buchheidt D, Vehreschild JJ et al (2012) Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro Surveill 17:20262

    PubMed  CAS  Google Scholar 

  21. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF (2012) Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 67:362–366

    Article  PubMed  CAS  Google Scholar 

  22. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA (2011) Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 55:4465–4468

    Article  PubMed  CAS  Google Scholar 

  23. van der Linden JW, Snelders E, Kampinga GA et al (2011) Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 17:1846–1854

    Article  PubMed  Google Scholar 

  24. Rodloff C, Koch D, Schaumann R (2011) Epidemiology and antifungal resistance in invasive candidiasis. Eur J Med Res 16:187–195

    Article  PubMed  CAS  Google Scholar 

  25. Alanio A, Sitterle E, Liance M et al (2011) Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother 66:371–374

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Baohong Ping, Department of Huiqiao, Nanfang Hospital, Guangdong, Guangzhou, 510515, China

    Baohong Ping, Yangmin Zhu, Ya Gao, Chunyan Yue & Bin Wu

Authors
  1. Baohong Ping
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yangmin Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ya Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chunyan Yue
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Baohong Ping.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ping, B., Zhu, Y., Gao, Y. et al. Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis. Ann Hematol 92, 831–839 (2013). https://doi.org/10.1007/s00277-013-1693-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1693-5

Keywords

Search

Navigation